Traumatic brain injury (TBI) is a major cause of long-term disability in the United States. Although more individuals survive traumatic brain injury than in the past, the survivors endure residual physical, cognitive, emotional and/or behavioral impairments from the cascade of biochemical responses resulting from TBI. The etiology of secondary brain injury is multi-factorial, with a host of likely inter- related processes: mitochondrial energy failure, excessive generation of reactive oxygen species, activation of destructive enzymes such as poly (ADP-ribose) polymerase (PARP), membrane disruption, neuronal death, thrombosis due to intravascular coagulation in small vessels, increased synaptic concentrations of excitatory amino acids, and activation of innate inflammatory responses. As secondary brain injury is multi-factoral, pharmacological strategies of neuroprotection must include drugs that target multiple mechanisms of the secondary injury. Translation of positive pre-clinical experimental studies into large randomized, controlled trials has been uniformly negative. The reason for the failure of the trials is probably due to many factors also. Specifically relevant to this proposal, the pre-clinical studies often failed to optimize the dose and dosage regimen, doses were often administered at non-clinically relevant times, i.e. pre-injury or immediately after injury with an overall absence of pharmacokinetic data to guide rational dosing. The primary objective of the proposal is to determine the optimal multi-drug therapy to promote neurological recovery in an animal model of traumatic brain injury using behavioral, histological and gene expression markers of neuroprotection to select the drugs and maximize the dosage regiment 1) by identifying combination therapy that targets the maximum number of molecular, cellular and biochemical secondary effects of TBI based on the pharmacologic properties of the drugs and 2) by determining the optimal dosage regimen in animals which would correlate to the proposed treatment of TBI in humans based on pharmacokinetic properties, Optimization includes the time of first dose, the dosage interval and the duration of treatment.
Trauma to the head is a major cause of long-term disability in the United States. People who survive a head injury often have chronic health problems, including physical, emotional and behavioral problems. The cause of the long-term health problems may be due to many different biochemical effects that start occurring immediately after the head injury as the brain attempts to heal itself. There have been many failed studies of single drugs in patients with head injuries suggesting that combinations of drugs may be more effective. This study will help to identify combinations of drugs that could be used to prevent the long-term effects.
|Vonder Haar, Cole; Anderson, Gail D; Elmore, Brandy E et al. (2014) Comparison of the effect of minocycline and simvastatin on functional recovery and gene expression in a rat traumatic brain injury model. J Neurotrauma 31:961-75|
|Vonder Haar, Cole; Smith, Travis R; French, Eric J et al. (2014) Simple tone discriminations are disrupted following experimental frontal traumatic brain injury in rats. Brain Inj 28:235-43|
|Anderson, G D; Peterson, T C; Farin, F M et al. (2013) The effect of nicotinamide on gene expression in a traumatic brain injury model. Front Neurosci 7:21|
|Anderson, Gail D; Farin, Federico M; Bammler, Theo K et al. (2011) The effect of progesterone dose on gene expression after traumatic brain injury. J Neurotrauma 28:1827-43|
|Vonder Haar, Cole; Anderson, Gail D; Hoane, Michael R (2011) Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury. Behav Brain Res 224:311-7|